September 26, 2016 7:24 AM ET

Biotechnology

Company Overview of ImmusanT, Inc.

Company Overview

ImmusanT, Inc., a biotechnology company, develops therapies and personalized diagnostics to treat patients with celiac disease. The company focusses on disease-modifying approach to induce immune tolerance in autoimmune diseases. It offers Nexvax2, a therapeutic vaccine for celiac disease; and a diagnostic and monitoring tool to improve celiac disease management. ImmusanT, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.

One Kendall Square

Suite B2004

Cambridge, MA 02139

United States

Founded in 2010

Phone:

617-299-8399

Fax:

617-300-8892

Key Executives for ImmusanT, Inc.

Founder, Chief Executive Officer, President and Director
Chief Financial Officer and Secretary pro tem
Director of Finance and Operations
Chief Medical Officer
Compensation as of Fiscal Year 2016.

ImmusanT, Inc. Key Developments

ImmusanT, Inc. Presents at Boston CEO Conference, May-31-2016 04:00 PM

ImmusanT, Inc. Presents at Boston CEO Conference, May-31-2016 04:00 PM. Venue: Four Seasons Boston, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Leslie J. Williams, Founder, Chief Executive Officer, President and Director.

ImmusanT, Inc. Presents at BBC BD Boston, Mar-09-2016 11:00 AM

ImmusanT, Inc. Presents at BBC BD Boston, Mar-09-2016 11:00 AM. Venue: The Westin Copley Place, 10 Huntington Avenue, Boston, MA 02116, United States. Speakers: Leslie J. Williams, Founder, Chief Executive Officer, President and Director.

ImmusanT, Inc. Announces Executive Appointments

ImmusanT, Inc. announced the appointment of Michael Cooreman, M.D., Ph.D., as Chief Medical Officer and Anita Treohan as Director of Clinical Operations. Dr. Cooreman brings to ImmusanT extensive experience in clinical development and translational medicine. As Chief Medical Officer, he will lead all clinical development programs, including the development of Nexvax2®, ImmusanT’s lead product candidate for the treatment of celiac disease. Ms. Treohan joins the company with diverse global clinical development and strategic experience across multiple therapeutic areas. As Director of Clinical Operations, Ms. Treohan will be responsible for the management of ImmusanT’s clinical programs, including the upcoming Phase 2 trials of Nexvax. Dr. Cooreman joins ImmusanT from Mitsubishi Tanabe, where he served as Executive Director for Clinical Research and Head of Metabolism, Infectious Diseases and Oncology. Most recently, Ms. Treohan served as Director of Clinical Operations at FORUM Pharmaceuticals Inc.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ImmusanT, Inc., please visit www.immusant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.